Zobrazeno 1 - 10
of 136
pro vyhledávání: '"Zarschler, K."'
Autor:
Krutzek, F., Donat, C., Ullrich, M., Zarschler, K., Ludik, M.-C., Feldmann, A., Rodrigues Loureiro, L. R., Kopka, K., Stadlbauer, S.
Publikováno v:
Publication date: 2023-05-06 Open accessDOI: 10.14278/rodare.2308Versions: 10.14278/rodare.2309License: CC-BY-4.0
Bei diesem Datensatz handelt es sich um die chemische Charakterisierung der Verbindungen, die in-vitro-, in-vivo- und ex-vivo-Daten.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4577::6d41eb4e7f2e46bc4957a299ddf6ad4a
https://www.hzdr.de/publications/Publ-36978-1
https://www.hzdr.de/publications/Publ-36978-1
Publikováno v:
61. DGN-Jahrestagung, 19.-22.04.2023, Leipzig, Deutschland
Nuklearmedizin 62(2023), 147
Nuklearmedizin 62(2023), 147
Ziel/Aim: Der Einsatz von Actinium-225 mit dem DOTA-Konjugat PSMA-617 befindet sich in der klinischen Entwicklung. DOTA ist jedoch nicht ideal, da hohe Temperaturen für die Markierung benötigt werden und der Komplex in vivo nicht stabil genug ist.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e06d04b4760193cbca78505ab4833b4b
https://www.hzdr.de/publications/Publ-37203-1
https://www.hzdr.de/publications/Publ-37203-1
Autor:
Trommer, J., Volesak Francova, P., Kučka, J., Emidio Costantini, P., Castagnola, V., Danielli, A., Calvaresi, M., Šefc, L., Benfenati, F., Kopka, K., Zarschler, K.
Publikováno v:
25th International Symposium on Radiopharmaceutical Chemistry, 22.-26.05.2023, Honolulu, Hawaii, USA
Objectives and Introduction Parkinson’s disease is caused by degeneration of nigro-striatal dopaminergic neurons and denervation of the target neurons in the neostriatum. The resulting disruption of dopaminergic modulation produces an imbalance bet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4577::0c1259db9c2c2f761de2537c14002d10
https://www.hzdr.de/publications/Publ-35867-1
https://www.hzdr.de/publications/Publ-35867-1
Autor:
Cieslik, P., Kubeil, M., Zarschler, K., Ullrich, M., Brandt, F., Anger, K., Wadepohl, H., Kopka, K., Bachmann, M., Pietzsch, J., Stephan, H., Comba, P.
Publikováno v:
Publication date: 2023-01-25 Closed accessDOI: 10.14278/rodare.2099Versions: 10.14278/rodare.2100
Bei diesem Datensatz handelt es sich um analytische Charakterisierungen (ESI-MS, HR-MS, MALDI-TOF-MS) und Radiomarkierungsuntersuchungen zum nonadentaten Bispidin-Chelator bzw. Bispidin-TATE Konjugat mit Lutetium-177, Indium-111 und/oder Actinium-225
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4577::a49a8ae45171b48568cb67da9cbe23fa
https://www.hzdr.de/publications/Publ-35458-1
https://www.hzdr.de/publications/Publ-35458-1
Autor:
Mamat, C., Reissig, F., Zarschler, K., Novy, Z., Petrik, M., Bendova, K., Kurfurstova, D., Bouchal, J., Pietzsch, H.-J., Kopka, K.
Publikováno v:
TERACHEM 2022, 14.-17.09.2022, Bressanone, Italien
The prostate-specific membrane antigen (PSMA) is expressed in approx. 80% of prostate cancer at considerably higher levels in tumor cells compared to healthy tissues. Its upregulation occurs in all stages of the disease. Therefore, PSMA has emerged a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4577::ad88d496b074af72fa0b8bf0c092d3ea
https://www.hzdr.de/publications/Publ-34552-1
https://www.hzdr.de/publications/Publ-34552-1
Autor:
Reissig, F., Zarschler, K., Ludik, M.-C., Novy, Z., Petrik, M., Bendova, K., Kurfürstova, D., Bouchal, J., Pietzsch, H.-J., Kopka, K., Mamat, C.
Publikováno v:
Nuclear Medicine and Biology 108-109(2022), S30-S31
24th International Symposium on Radiopharmaceutical Sciences, 29.05.-02.06.2022, Nantes, Frankreich
24th International Symposium on Radiopharmaceutical Sciences, 29.05.-02.06.2022, Nantes, Frankreich
Objectives The prostate-specific membrane antigen (PSMA) is expressed in most cases of prostate cancer at considerably higher levels in tumor cells compared to healthy tissues [1-3] and its upregulation occurs in all stage of the disease [4, 5]. Ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::13cddfd1c9339bec8c1d20ecf01f164c
https://www.hzdr.de/publications/Publ-34544-2
https://www.hzdr.de/publications/Publ-34544-2
Autor:
Kopp, I., Kubeil, M., Cieslik, P., Brandt, F., Zarschler, K., Ullrich, M., Pietzsch, J., Bachmann, M., Kopka, K., Stephan, H., Comba, P.
Publikováno v:
Jahrestagung FG Nuklearchemie, 04.-06.10.2022, Bergisch Gladbach, Deutschland
Bispidines (3,7-diazabicyclo[3.3.1]nonane) and their derivatives act as bifunctional chelators (BFC), combining the advantages of multidentate macrocyclic and acyclic ligands (e.g., high kinetic inertness, rapid radiolabelling under mild conditions)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4577::1092c72f16ca4633e6e73508ea7a5d96
https://www.hzdr.de/publications/Publ-35400-1
https://www.hzdr.de/publications/Publ-35400-1
Publikováno v:
Australian Society of Molecular Imaging (ASMI) 2022, 06.-07.10.2022, Melbourne, Australia
Bispidines (3,7-diazabicyclo[3.3.1]nonane) and their derivatives act as bifunctional chelating agents (BFCAs). Combining the advantages of highly preorganised rigid macrocyclic ligands and the flexibility of open-chain ligands, bispidines are able to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4577::a412b3d161ad6670bd096cb75195d7b7
https://www.hzdr.de/publications/Publ-35395-1
https://www.hzdr.de/publications/Publ-35395-1
Autor:
Reissig, F., Bauer, D., Zarschler, K., Novy, Z., Bendova, K., Kopka, K., Pietzsch, H.-J., Petrik, M., Mamat, C.
Publikováno v:
Cancers 13(2021)8, 1974
Currently, targeted alpha therapy is one of the most investigated topics in radiopharmaceutical cancer management. Especially, the alpha emitter 225 Ac provides excellent nuclear properties and is gaining increasing popularity for the treatment of va
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4577::d37875511eea0d8ef03ab3d3ae870c95
https://www.hzdr.de/publications/Publ-32369-1
https://www.hzdr.de/publications/Publ-32369-1
Autor:
Reissig, F., Bauer, D., Zarschler, K., Novy, Z., Bendova, K., Ludik, M.-C., Kopka, K., Pietzsch, H.-J., Petrik, M., Mamat, C.
Publikováno v:
EANM'21 virtual (34th congress), 20.-23.10.2021, Wien, Österrreich
Targeted alpha therapy is currently one of the most intensively investigated topics in radiopharmaceutical sciences and cancer management in nuclear medicine. Especially, the alpha emitter 225Ac provides excellent physical and chemical properties (t1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4577::cc000657ad11f4fd02911b8231b0c2e9
https://www.hzdr.de/publications/Publ-32661-1
https://www.hzdr.de/publications/Publ-32661-1